The goal of this clinical trial is to learn whether adding cilostazol to aspirin or clopidogrel prevents stroke and heart attack in people who have had a stroke or mini-stroke.
Diagnosis of stroke or mini-stroke (also called TIA) within the last 180 days
Currently taking aspirin or clopidogrel (not both) to prevent another stroke
Had a spontaneous brain bleed within the last 2 years.
Moderate to severe heart failure.
Life expectancy is less than 6 months.
Parallel
Cilostazol 100 mg
DrugCilostazol 100 mg tablet taken orally twice daily following an initial 2-week period during which cilostazol is dosed at 100 mg tablet taken orally once daily to maximize tolerability.
Placebo
DrugPlacebo 100 mg tablet twice taken orally daily following an initial 2-week period during which placebo is dosed at 100 mg taken orally once daily to maximize tolerability.
Major adverse cardiovascular event (MACE)
Time to stroke (ischemic and hemorrhagic), acute myocardial infarction, or vascular death
Ischemic stroke
Time to ischemic stroke
Major hemorrhage
Time to major hemorrhage
Click on the lead sponsor to view all of their trials.
Stanford University
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator
Yale University
Collaborator
University of Cincinnati
Collaborator
Medical University of South Carolina
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
